Wojewodzki Szpital Im. Sw.Ojca Pio W Przemyslu

At Wojewodzki Szpital Im. Sw.Ojca Pio W Przemyslu, the strongest research focus is cardiovascular medicine, with studies centered on myocardial infarction, heart failure, atrial fibrillation, hypertension, and atherosclerotic cardiovascular disease. These trials are designed to test new treatments, improve prevention, and better understand how to reduce serious heart-related complications.

• Research on treatments after acute myocardial infarction to lower future cardiovascular risk
• Studies in heart failure, including preserved and reduced ejection fraction forms, to improve outcomes and quality of life
• Trials in atrial fibrillation and stroke prevention to evaluate safer and more effective blood-thinning strategies
• Work on hypertension, obesity, and related cardiometabolic risk to support earlier intervention

This broad program reflects a strong interest in both acute and chronic heart conditions, with several studies also exploring inflammation, iron deficiency, and other factors that can influence cardiac health.

The site also conducts extensive cancer research across lung cancer, gastric and gastroesophageal cancers, breast cancer, bladder cancer, prostate cancer, renal cell carcinoma, hepatocellular carcinoma, and head and neck cancers. Many of these trials aim to assess whether new combinations of therapies can improve survival, delay disease progression, or support earlier treatment in difficult-to-treat cancers.

• Studies in non-small cell lung cancer and small cell lung cancer to evaluate newer treatment combinations and targeted approaches
• Trials in gastric and gastroesophageal junction cancer focused on improving outcomes in advanced disease
• Research in bladder cancer and prostate cancer examining better options for high-risk or metastatic disease
• Investigations in breast cancer, renal cancer, liver cancer, and head and neck cancer to test emerging immunotherapy and targeted strategies

The oncology portfolio includes both locally advanced and metastatic settings, showing a clear emphasis on improving treatment effectiveness for patients with limited standard options.

Research in digestive system diseases includes studies on gastric cancer, gastroesophageal junction adenocarcinoma, biliary tract cancer, and hepatocellular carcinoma. The main goal is to evaluate new therapies and treatment combinations that may help control cancer growth and reduce recurrence after surgery or in advanced disease.

• Trials in gastric and gastroesophageal junction cancer exploring better first-line and perioperative treatment options
• Studies in biliary tract cancer looking at ways to delay recurrence after curative surgery
• Research in hepatocellular carcinoma assessing new systemic treatment strategies

These studies reflect a strong interest in cancers of the upper digestive tract, with an emphasis on improving survival and disease control.

The site is also active in nutritional and metabolic research, including obesity, overweight, lipoprotein(a) elevation, and related cardiometabolic conditions. These trials are mainly designed to test new approaches for lowering long-term cardiovascular risk and improving metabolic health.

• Studies in obesity and overweight examining therapies that may support weight-related risk reduction
• Research on elevated lipoprotein(a) aimed at reducing future cardiovascular events
• Trials linking metabolic health with heart failure and broader cardiovascular prevention

This area connects closely with the cardiology department’s broader focus on prevention, risk reduction, and long-term patient outcomes.

A major part of the research portfolio involves respiratory tract diseases, especially non-small cell lung cancer and small cell lung cancer. These studies are aimed at improving treatment effectiveness, testing innovative immunotherapy and targeted therapy combinations, and finding better options for advanced or high-risk disease.

• Trials in non-small cell lung cancer across early, locally advanced, and metastatic settings
• Research in small cell lung cancer focused on extending survival and controlling disease progression
• Studies of EGFR, HER2, KRAS G12C, and PD-L1-related lung cancer subgroups to support more personalized care

The breadth of lung cancer research at this site suggests a strong commitment to advancing precision medicine in one of the most active therapeutic areas.

The site also participates in research on cell physiological phenomena, mainly through studies that examine inflammation, cardiac remodeling, and biomarker changes linked to disease progression. These trials are intended to improve understanding of how biological processes affect treatment response, particularly in heart failure and after myocardial infarction.

• Studies assessing how biological markers change in heart failure and after heart attack
• Research into inflammation and cardiac structure as part of cardiovascular risk management
• Trials aimed at deepening understanding of disease mechanisms to support future therapy development

This area adds a translational dimension to the site’s work, linking clinical care with mechanistic research.